Features of tuberculosis diagnosis in the COVID-19
https://doi.org/10.22625/2072-6732-2021-13-1-117-123
Abstract
2020 began with the most significant pandemic COVID-19 in the history of this century. The epidemiology indicators are growing every day. The spread of COVID-19 may affect an increase in the incidence of tuberculosis, despite a decrease in the incidence rate that is associated with objective difficulties in detecting tuberculosis against the background of COVID-19 and severe complications after the new coronavirus infection. Tuberculosis is one of the infectious diseases, and the problem of its spread continues to be relevant throughout the World. The effect of the SARS-CoV-2 virus can cause certain difficulties in the diagnosis and treatment of tuberculosis infection. The possibility of concomitant these infectious diseases can affect the clinical course of tuberculosis, an influence on mortality of the disease, but at the same time, there is a decrease in the number of cases that is not objective. The authors analyzed the currently published data on detecting tuberculosis in the conditions of the COVID-19 problem and presented difficulties in the diagnosis of COVID-19 and TB concomitant diseases with a description in the clinical case.
About the Authors
O. L. Ekaterincheva
City Tuberculous Hospital № 2
Russian Federation
Russian Federation
Saint-Petersburg
A. M. Malkova
Saint-Petersburg State University
Russian Federation
Russian Federation
Saint-Petersburg
V. E. Karev
Children’s Research and Clinical Center for Infectious Diseases; National Medical Research Centre named after V.A. Almazov
Russian Federation
Russian Federation
Saint-Petersburg
I. V. Kudryavtsev
Saint-Petersburg State University; Institute of Experimental Medicine
Russian Federation
Russian Federation
Saint-Petersburg
Yu. S. Zinchenko
Saint-Petersburg State University; Saint-Petersburg Scientific Research Institute of Phthisiopulmonology
Russian Federation
Russian Federation
Saint-Petersburg
T. B. Potepun
City Tuberculous Hospital № 2
Russian Federation
Russian Federation
Saint-Petersburg
D. A. Kudlai
First Moscow State Medical University named after I.M. Sechenov; Institute of Immunology
Russian Federation
Russian Federation
Moscow
A. A. Starshinova
National Medical Research Centre named after V.A. Almazov
Russian Federation
Russian Federation
Saint-Petersburg
References
1. Stochino C, Villa S, Zucchi P, Parravicini P, Gori A, Raviglione MC. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur Respir J. 2020;56(1):2001708. doi:10.1183/13993003.01708-2020.
2. Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. medRxiv and bioRxiv. DOI: 10.1101/2020.04.28.20079582
3. WHO guidelines on tuberculosis infection prevention and control. – Geneva: WHO (2019) 265.
4. World Health Organization. Global tuberculosis report 2018. – Geneva: WHO (2018) 270.
5. WHO consolidated guidelines on drug-resistant tuberculosis treatment. – 2019. – 96p. ISBN 978-92-4-155052-9.
6. Guglielmetti L, Veziris N, Aubry A, Brossier F, Bernard C, Sougakoff W, Jarlier V, Robert J. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a casecase study. Int J Tuber. and lung dis. 2018; 22(1):54–59. DOI: 10.5588/ijtld.17.0387.
7. World Health Organization. Global tuberculosis report 2017. – Geneva: WHO, 2017. – 250p.
8. Al-Omari A, Alhuqbani WN, Zaidi ZRA, Al-Subaie FM, Alanoud M, Hindi AM, Abogosh KA et al. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: A descriptive cross-sectional study. Journal of Infection and Public Health. 2020; 1876-0341. doi.org/10.1016/j.jiph.2020.09.003
9. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020. doi: 10.1016/j.jinf.2020.04.017
10. Hilda JN, Das S, Tripathy SP, Hanna LE. Role of neutrophils in tuberculosis: A bird’s eye view. Innate Immun. 2020;26(4):240-247. doi: 10.1177/1753425919881176
11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506. doi: 10.1016/S01406-736(20)30183-5.
12. Faqihi F., Alharthy A., Noor A., Balshi A., Balhamar A., Karakitsos D. COVID-19 in a patient with active tuberculosis: A rare case-report RSS . Respiratory Medicine Case Reports, 2020; 31: https://doi.org/10.1016/j.rmcr.2020.101146).
13. Interim guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)” (version 6 of 04.24.2020) -165s.
14. Dovgalyuk I.F., Skvortsova L.A., Ovchinnikova Yu.E., Starshinova A.A. Pathomorphism and diagnosis of tuberculosis of intrathoracic lymph nodes in children // Problems of tuberculosis and lung diseases. 2004. – No. 1. – S.33-36.
15. Starshinova A., Zhuravlev V., Dovgaluk I., Panteleev A., Manina V., Zinchenko U., Istomina E., Pavlova M., Yablonskiy P. A Comparison of Intradermal Test with Recombinant Tuberculosis Allergen (Diaskintest) with Other Immunologic Tests in the Diagnosis of Tuberculosis Infection. International Journal of Mycobacteriology. 2018; 1(2):32–39.
16. Starshinova A.A., Dovgalyk I., Malkova A.M., Zinchenko Yu.S., Pavlova M.V., Belyaeva E., Basantsova N.Yu., Nazarenko M., Kudlai D.A., Yablonskiy P. Recombinant tuberculosis allergen (Diaskintest ®) in tuberculosis diagnostic in Russia (meta-analysis). International Journal of Mycobacteriology. 2020. Т. 9. № 4. С. 335-346.
17. Starshinova A.A., Dovgalyuk I.F. Tuberculosis in the structure of comorbid pathology in patients with COVID-19. Pacific Journal. 2021; 1: 1609-1175.
18. Hogan BA, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker Ch, Hamlet A, Smith JA, Winskill P, Verity R, Baguelin M, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob Health 2020; 8: e1132–41 Published Online July 13, 2020 https://doi.org/10.1016/S2214-109X(20)30288-6.
19. World Health Organization. Global tuberculosis report 2020. – Geneva: WHO. 232. ISBN 978-92-4-001313-1
20. Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, Xia WG, Zhang JX, Miao Q. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J Infect. 2020;81(1):e51-e60. doi: 10.1016/j.jinf.2020.04.012
21. Zhang B, Zhou X, Zhu Ch, Feng F, Qiu Y, Feng J, Jia Q et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci. 2020; 7: 157. doi: 10.3389/fmolb.2020.00157.
22. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Li Zhu, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang F-S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X.
23. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020. 10.1126/science.abb8925.
24. Ciceri F., Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, Peccatori J, D’Angelo A, De Cobelli F, Rovere-Querini P, Tresoldi M, Dagna L, Zangrillo A. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine. 2020;22(2):95-97. PMID: 32294809.
25. Starshinova A.A., Kushnareva E.A., Malkova A.M., Dovgalyuk I.F., Kudlai D.A. New coronavirus infection: features of the clinical course, the possibility of diagnosis, treatment and prevention of infection in adults and children. Questions of modern pediatrics. 2020; 19 (2): 42-50.
26. Chen Y., Wang Y., Fleming J., Yu Y., Gu Y., Liu Ch., Fan L., Wang X., Cheng M., Lijun Bi L., Liu Y. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv.2020; doi.org/10.1101/2020.03.10.20033795.
Review
For citations:
Ekaterincheva O.L., Malkova A.M., Karev V.E., Kudryavtsev I.V., Zinchenko Yu.S., Potepun T.B., Kudlai D.A., Starshinova A.A. Features of tuberculosis diagnosis in the COVID-19. Journal Infectology. 2021;13(1):117-123. (In Russ.) https://doi.org/10.22625/2072-6732-2021-13-1-117-123
Views:
1888
.png)
.png)
Email this article 